Psychedelic Institute of Mental Health & Family Therapy
Psychedelic Institute of Mental Health & Family Therapy
Telehealth Ketamine Therapists
⌘K
Contact
Psychedelic Institute of Mental Health & Family Therapy
ketamine

Spotlight: Ketamine for treatment-resistant post-traumatic stress disorder: double-blind active-controlled randomised crossover study (Beaglehole, et al, 2025)

"We provide preliminary support for the efficacy and tolerability of i.m. ketamine in a community sample of individuals with PTSD."
Michael DeMarco, PhD

by Michael DeMarco, PhD

Ketamine for treatment-resistant post-traumatic stress disorder: double-blind active-controlled randomised crossover study - PubMed
We provide preliminary support for the efficacy and tolerability of i.m. ketamine in a community sample of individuals with PTSD. Further work is required to establish the optimal dosing regimen and longer-term role of ketamine in treatment of PTSD, but our findings are encouraging given the well-kn …
PubMedBen Beaglehole

(2025): "We provide preliminary support for the efficacy and tolerability of i.m. ketamine in a community sample of individuals with PTSD."

More like this

Naltrexone in the Treatment of Ketamine Use Disorders: A Case Report and Literature Review (Verma, et al, 2025)

"findings consistent w/ 2 prior reports - use of naltrexone in KUDs at the dosage of 50 mg/day successfully helped patients achieve abstinence... naltrexone reduces antidepressant effects of ketamine, indicating overlap between opioid system & ketamine's NMDA receptor activity. "

Spotlight: The transformational power of psychedelics: catalysts for creativity, consciousness, and mental health (Du, et al, 2025)

"Psychedelics, such as psilocybin, lysergic acid diethylamide (LSD), ketamine, and N,N-dimethyltryptamine (DMT), have captured the attention of scientists, artists, and seekers alike for their profound ability to alter consciousness and inspire creativity."

Spotlight: Efficacy of Intravenous Racemic Ketamine on Global Severity and Individual Symptoms of Depression: An Exploratory Retrospective Analysis (Landrum, et al, 2025)

" Maintenance intravenous racemic ketamine therapy demonstrated significant, persistent, and broad efficacy for treatment-resistant depression ...Side effect burden was no greater in higher doses as compared with lower. "

Spotlight: Ketamine's Role in Neuroinflammation and Neuroprotection Across Neurological and Psychiatric Disorders: A Narrative Review (Silva, et al, 2025)

"Our findings indicate that ketamine reduces excitotoxicity and inflammation, which may contribute to neuroprotection in acute neurological injuries. These insights underscore ketamine's potential as an adjunctive neuroprotective agent, warranting further clinical investigation...

Spotlight: First study to compare two ketamine therapies for patients with severe depression

IV ketamine found to offer faster response with greater improvements than FDA-approved intranasal esketamine (Spravato)

Characteristics of Ongoing Clinical Trials of Psychogenic Substances for Psychiatric Disorders (Havlik, et al, 2025)

"The most frequently studied substances were psilocybin (n=64; 35.4%) and ketamine (n=61; 33.7%). Trials were notably concentrated within a small number of leading academic institutions."
Mastodon Mastodon